{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:54:29Z","timestamp":1783814069304,"version":"3.55.0"},"reference-count":63,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Systemic mastocytosis (SM) is a hematologic neoplasm with abnormal accumulation of mast cells in various organ systems such as the bone marrow, other visceral organs and skin. So far, only little is known about epigenetic changes contributing to the pathogenesis of SM. In the current article, we provide an overview of epigenetic changes that may occur and be relevant to mastocytosis, including mutations in genes involved in epigenetic processes, such as TET2, DNMT3A and ASXL1, and global and gene-specific methylation patterns in neoplastic cells. Moreover, we discuss methylation-specific pathways and other epigenetic events that may trigger disease progression in mast cell neoplasms. Finally, we discuss epigenetic targets and the effects of epigenetic drugs, such as demethylating agents and BET-targeting drugs, on growth and viability of neoplastic mast cells. The definitive impact of these targets and the efficacy of epigenetic therapies in advanced SM need to be explored in future preclinical studies and clinical trials.<\/jats:p>","DOI":"10.3390\/ijms22062964","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T11:38:58Z","timestamp":1615808338000},"page":"2964","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2153-4864","authenticated-orcid":false,"given":"Edyta","family":"Reszka","sequence":"first","affiliation":[{"name":"Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, 91-348 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3946-3964","authenticated-orcid":false,"given":"Ewa","family":"Jab\u0142o\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, 91-348 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Wieczorek","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, 91-348 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5095","authenticated-orcid":false,"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-4408","authenticated-orcid":false,"given":"Michel","family":"Arock","sequence":"additional","affiliation":[{"name":"Department of Hematological Biology, Piti\u00e9-Sap\u00eatri\u00e8re Hospital, Sorbonne University, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-5512","authenticated-orcid":false,"given":"Gunnar","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, SE-171 76 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-0693","authenticated-orcid":false,"given":"Bogus\u0142aw","family":"Nedoszytko","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-211 Gdansk, Poland"},{"name":"Invicta Fertility and Reproductive Center, Molecular Laboratory, Polna 64, 81-740 Sopot, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Niedoszytko","sequence":"additional","affiliation":[{"name":"Department of Allergology, Medical University of Gdansk, 80-211 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: Delineation from immunologic diseases and non\u2013mast cell hematopoietic neoplasms","volume":"114","author":"Valent","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Valent, P., Akin, C., Gleixner, K.V., Sperr, W.R., Reiter, A., Arock, M., and Triggiani, M. (2019). Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122976"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: A consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_8","first-page":"1420","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): A consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molimm.2014.03.013","article-title":"Molecular basis of mast cell disease","volume":"63","author":"Soucie","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.18632\/oncotarget.4213","article-title":"Mastocytosis: A mutated KIT receptor induced myeloproliferative disorder","volume":"6","author":"Chatterjee","year":"2015","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0065-2776(08)60879-2","article-title":"Cell surface structures on human basophils and mast cells: Biochemical and functional characterization","volume":"Volume 52","author":"Valent","year":"1992","journal-title":"Advances in Immunology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.V80.9.2237.2237","article-title":"Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor\/kit-ligand in long-term culture","volume":"80","author":"Valent","year":"1992","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-5699(94)90153-8","article-title":"The riddle of the mast cell: Kit (CD117)-ligand as the missing link?","volume":"15","author":"Valent","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Teodosio","year":"2006","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.V126.23.828.828","article-title":"ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis","volume":"126","author":"Pardanani","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.leukres.2014.07.010","article-title":"Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412","volume":"38","author":"Visconte","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.13560","article-title":"Concurrent activating KIT mutations in systemic mastocytosis","volume":"173","author":"Lasho","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/epi.11.22","article-title":"Epigenetics and lifestyle","volume":"3","author":"Baccarelli","year":"2011","journal-title":"Epigenomics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fcell.2014.00049","article-title":"Epigenetics across the human lifespan","volume":"2","author":"Kanherkar","year":"2014","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0022034509335868","article-title":"Epigenetics: Connecting environment and genotype to phenotype and disease","volume":"88","author":"Barros","year":"2009","journal-title":"J. Dent. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00439-013-1373-5","article-title":"Cancer genomics identifies disrupted epigenetic genes","volume":"133","author":"Esteller","year":"2014","journal-title":"Hum. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/leu.2017.183","article-title":"SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis","volume":"32","author":"Martinelli","year":"2018","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ng.2894","article-title":"Identification of functional cooperative mutations of SETD2 in human acute leukemia","volume":"46","author":"Zhu","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1074\/jbc.M113.546895","article-title":"Proteolytic histone modification by mast cell tryptase, a serglycin proteoglycan-dependent secretory granule protease","volume":"289","author":"Melo","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2016.11.044","article-title":"Tryptase-catalyzed core histone truncation: A novel epigenetic regulatory mechanism in mast cells","volume":"140","author":"Melo","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.3389\/fimmu.2018.02414","article-title":"Epigenetic regulation via altered histone acetylation results in suppression of mast cell function and mast cell-mediated food allergic responses","volume":"9","author":"Krajewski","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ungerstedt, J.S. (2018). Epigenetic modifiers in myeloid malignancies: The role of histone deacetylase inhibitors. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103091"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9647","DOI":"10.18632\/oncotarget.14181","article-title":"Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis","volume":"8","author":"Lyberg","year":"2017","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ajh.24426","article-title":"Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Traina, F., Visconte, V., Jankowska, A.M., Makishima, H., O\u2019Keefe, C.L., Elson, P., Han, Y., Hsieh, F.H., Sekeres, M.A., and Mali, R.S. (2012). Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043090"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Damaj, G., Joris, M., Chandesris, O., Hanssens, K., Soucie, E., Canioni, D., Kolb, B., Durieu, I., Gyan, E., and Livideanu, C. (2014). ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085362"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2013.092007","article-title":"Epigenetics in the hematologic malignancies","volume":"99","author":"Fong","year":"2014","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/1878-0261.12744","article-title":"The DNA methylation landscape of hematological malignancies: An update","volume":"14","author":"Blecua","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrm3589","article-title":"TETonic shift: Biological roles of TET proteins in DNA demethylation and transcription","volume":"14","author":"Pastor","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/1744666X.2019.1596800","article-title":"Recent advances in our understanding of mast cell activation\u2014Or should it be mast cell mediator disorders?","volume":"15","author":"Theoharides","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"De Vita, S., Schneider, R.K., Garcia, M., Wood, J., Gavillet, M., Ebert, B.L., Gerbaulet, A., Roers, A., Levine, R.L., and Mullally, A. (2014). Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096209"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.celrep.2016.04.044","article-title":"TET2 regulates mast cell differentiation and proliferation through catalytic and non-catalytic activities","volume":"15","author":"Montagner","year":"2016","journal-title":"Cell Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2018.03.025","article-title":"Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo","volume":"23","author":"Jeong","year":"2018","journal-title":"Cell Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E1490","DOI":"10.1073\/pnas.1616420114","article-title":"Dnmt3a restrains mast cell inflammatory responses","volume":"114","author":"Leoni","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ejh.12537","article-title":"Reduced DNA methylation and hydroxymethylation in patients with systemic mastocytosis","volume":"95","author":"Leoni","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbagrm.2015.06.015","article-title":"lncRNAs and microRNAs with a role in cancer development","volume":"1859","author":"Liz","year":"2016","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Shefler, I., Salamon, P., and Mekori, Y.A. (2019). MicroRNA involvement in allergic and non-allergic mast cell activation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092145"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1186\/gb-2005-6-8-r71","article-title":"MicroRNA profiling of the murine hematopoietic system","volume":"6","author":"Monticelli","year":"2005","journal-title":"Genome Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4049\/jimmunol.182.1.433","article-title":"MicroRNA-221\u2013222 regulate the cell cycle in mast cells","volume":"182","author":"Mayoral","year":"2009","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"18389","DOI":"10.3402\/jev.v1i0.18389","article-title":"Characterization of mRNA and microRNA in human mast cell-derived exosomes and their transfer to other mast cells and blood CD34 progenitor cells","volume":"1","author":"Valadi","year":"2012","journal-title":"J. Extracell. Vesicles"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4049\/jimmunol.178.1.378","article-title":"Distinct and shared transcriptomes are regulated by microphthalmia-associated transcription factor isoforms in mast cells","volume":"178","author":"Shahlaee","year":"2007","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.V88.4.1225.bloodjournal8841225","article-title":"Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice","volume":"88","author":"Tsujimura","year":"1996","journal-title":"Blood"},{"key":"ref_56","first-page":"3629","article-title":"KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation","volume":"117","author":"Lee","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_57","first-page":"6411","article-title":"MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1","volume":"113","author":"Garzon","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wang, Q., Zhao, D.-Y., Xu, H., Zhou, H., Yang, Q.-Y., Liu, F., and Zhou, G.-P. (2015). Down-regulation of microRNA-223 promotes degranulation via the PI3K\/Akt pathway by targeting IGF-1R in mast cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123575"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2174\/092986708784534947","article-title":"Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias","volume":"15","author":"Leone","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_60","first-page":"2989","article-title":"DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer","volume":"33","author":"Gnyszka","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_61","first-page":"4242","article-title":"5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: Role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand","volume":"119","author":"Ghanim","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/leu.2015.138","article-title":"Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia","volume":"29","author":"Wedeh","year":"2015","journal-title":"Leukemia"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/6\/2964\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:35:43Z","timestamp":1760160943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/6\/2964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ijms22062964"],"URL":"https:\/\/doi.org\/10.3390\/ijms22062964","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]}}}